

SKYEPHARMA PLC
Form 6-K
April 23, 2007

**SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of April, 2007

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

Once-Daily REQUIP LP Extended-Release Tablets Approved in France

Edgar Filing: SKYEPHARMA PLC - Form 6-K

LONDON, UK, Monday, April 23, 2007 - SkyePharma PLC (LSE:SKP; NASDAQ: SKYE) today announced received in France for ropinirole prolonged release tablets (which will be marketed as *REQUIP* release tablet of ropinirole is taken once daily, and is indicated for the treatment of Parkinson's disease. SkyePharma's partner for the product, GlaxoSmithKline has also received approval in Slovakia, Slovenia, Latvia and will gain further marketing authorisations in other countries.

On 13 April, SkyePharma announced that the United States Food and Drug Administration had accepted for approval to market the product in the US. *REQUIP* LP has been designed to provide a steady state plasma level help reduce blood plasma fluctuations over 24 hours.

Frank Condella, CEO of SkyePharma, commented: "We are pleased to announce the French approval of the roll-out of ropinirole prolonged release tablets across the Continent. In the coming weeks we will receive European approvals and will continue the roll-out of this important product across other member states."

For further information please contact:

SkyePharma PLC	Frank Condella Ken Cunningham Peter Grant	+44 20 7491 1700
Financial Dynamics (UK Enquiries)	David Yates Deborah Scott	+44 20 7831 3100
Trout Group (US Enquiries)	Christine Labaree Seth Lewis	+1 617 583 1300

NOTES TO EDITORS

About Ropinirole

Ropinirole is a non-ergot dopamine agonist currently marketed as *REQUIP*® (ropinirole HCl) Tablet. It has an indication in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease, taken three times a day. *REQUIP* LP uses SkyePharma's proprietary Geomatrix™ technology and has been designed to have a simpler and faster titration schedule.

Our partner GSK conducted two pivotal studies to support of the registration of ropinirole prolonged release tablets. The first study was a ropinirole monotherapy study in early PD, and the other was an adjunct study with levodopa. Both studies confirmed the efficacy of ropinirole prolonged release tablets, in terms of symptomatic control and their daily activities.

About Parkinson's Disease

Parkinson's disease is a chronic, progressive and debilitating neurological condition that affects movement and balance. Researchers have determined that Parkinson's disease involves pathways in the brain that are not functioning properly. Patients with Parkinson's disease experience a reduction in dopamine, which is needed to communicate messages about movement, resulting in the symptoms of Parkinson's disease. The symptoms include (slower-than-normal voluntary movements), rigidity (stiffness), tremor (involuntary shaking) and loss of balance.

In Europe, an estimated 800,000 people live with PD, with about 75,000 new cases diagnosed every year. It is a key to helping them maintain a good quality of life and minimising long-term side effects. A significant barrier to positive patient outcomes in PD.

About SkyePharma PLC

Using its proprietary drug delivery technologies, SkyePharma develops new formulations of drugs to provide advantage and life-cycle extension. The Company has ten approved products in the areas of oral, injectable and transdermal, are marketed throughout the world by leading pharmaceutical companies.

For more information, visit www.skyepharma.com

About GlaxoSmithKline

GlaxoSmithKline, with U.S. operations in Philadelphia and Research Triangle Park, N.C., is one of the world's leading pharmaceutical and health care companies.

Edgar Filing: SKYEPHARMA PLC - Form 6-K

1. In the other member states of the European Union, the product suffixes under consideration
REQUIP DEPOT . REQUIP, MODUTAB AND DEPOT are trademarks of the GlaxoSmithKline group of com
- i European Federation of Pharmaceutical Industries and Associations:
<http://www.efpia.org/Content/Default.asp?PageID=133> (Accessed April 2007) .

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ John Murphy

Name: John Murphy
Title: Company Secretary

Date: April 23, 2007